- Home
- LUNG vs ADCT Comparison
LUNG vs ADCT Comparison
Compare LUNG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- ADCT
- Stock Information
- Founded
- LUNG 1995
- ADCT 2011
- Country
- LUNG United States
- ADCT Switzerland
- Employees
- LUNG N/A
- ADCT N/A
- Industry
- LUNG Industrial Specialties
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- ADCT Health Care
- Exchange
- LUNG Nasdaq
- ADCT Nasdaq
- Market Cap
- LUNG 251.5M
- ADCT 224.3M
- IPO Year
- LUNG 2020
- ADCT 2020
- Fundamental
- Price
- LUNG $6.23
- ADCT $1.97
- Analyst Decision
- LUNG Buy
- ADCT Strong Buy
- Analyst Count
- LUNG 6
- ADCT 5
- Target Price
- LUNG $11.92
- ADCT $8.00
- AVG Volume (30 Days)
- LUNG 252.9K
- ADCT 1.7M
- Earning Date
- LUNG 02-19-2025
- ADCT 11-07-2024
- Dividend Yield
- LUNG N/A
- ADCT N/A
- EPS Growth
- LUNG N/A
- ADCT N/A
- EPS
- LUNG N/A
- ADCT N/A
- Revenue
- LUNG $79,302,000.00
- ADCT $70,717,000.00
- Revenue This Year
- LUNG $22.26
- ADCT $6.58
- Revenue Next Year
- LUNG $18.72
- ADCT $11.78
- P/E Ratio
- LUNG N/A
- ADCT N/A
- Revenue Growth
- LUNG 22.34
- ADCT N/A
- 52 Week Low
- LUNG $5.46
- ADCT $1.28
- 52 Week High
- LUNG $14.84
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- LUNG 41.37
- ADCT 43.59
- Support Level
- LUNG $5.72
- ADCT $1.90
- Resistance Level
- LUNG $6.28
- ADCT $2.21
- Average True Range (ATR)
- LUNG 0.40
- ADCT 0.42
- MACD
- LUNG -0.03
- ADCT -0.03
- Stochastic Oscillator
- LUNG 19.85
- ADCT 9.76
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.